Abstract
Cisplatin, carboplatin and oxaliplatin continue to be among the most efficient anticancer drugs in world-wide clinical use so far. In particular, cisplatin has shown a remarkable therapeutic efficacy in a broad spectrum of solid tumors and outstanding activity against metastatic testicular germ-cell cancer with cure rates of about 90% of cases. Nevertheless, the dose-limiting severe toxic side-effects of platinum-based chemotherapy, the problem of inherent or therapy-induced resistance, the limited activity in a range of tumors, and the meager tumor selectivity are the motivation for tremendous efforts and inventions in the development of novel anticancer platinum drugs. This article reviews the most recent patents in this field of research, covering the following strategies in the design of promising anticancer platinum complexes: (i) synthesis of new anticancer platinum complexes, using combinatorial chemistry and high throughput synthesis and screening, (ii) activation of platinum complexes in the tumor tissue, (iii) accumulation of platinum complexes at the tumor site, (iv) novel platinum complexes, displaying activity against cisplatin resistant cells and as inhibitors of specific biological functions, and (v) direct derivatives of classical anticancer platinum drugs in clinical use.
Keywords: platinum complexes, cisplatin, carboplatin, oxaliplatin, synthesis, novel derivatives, combinatorial chemistry, high throughput synthesis and screening, reduction of side-effects, activation
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Developments in the Field of Anticancer Platinum Complexes
Volume: 1 Issue: 2
Author(s): Mathea Sophia Galanski*
Affiliation:
- Institute of Inorganic Chemistry – Bioinorganic, Environmental and Radiochemistry, University of Vienna, Vienna, Austria
Keywords: platinum complexes, cisplatin, carboplatin, oxaliplatin, synthesis, novel derivatives, combinatorial chemistry, high throughput synthesis and screening, reduction of side-effects, activation
Abstract: Cisplatin, carboplatin and oxaliplatin continue to be among the most efficient anticancer drugs in world-wide clinical use so far. In particular, cisplatin has shown a remarkable therapeutic efficacy in a broad spectrum of solid tumors and outstanding activity against metastatic testicular germ-cell cancer with cure rates of about 90% of cases. Nevertheless, the dose-limiting severe toxic side-effects of platinum-based chemotherapy, the problem of inherent or therapy-induced resistance, the limited activity in a range of tumors, and the meager tumor selectivity are the motivation for tremendous efforts and inventions in the development of novel anticancer platinum drugs. This article reviews the most recent patents in this field of research, covering the following strategies in the design of promising anticancer platinum complexes: (i) synthesis of new anticancer platinum complexes, using combinatorial chemistry and high throughput synthesis and screening, (ii) activation of platinum complexes in the tumor tissue, (iii) accumulation of platinum complexes at the tumor site, (iv) novel platinum complexes, displaying activity against cisplatin resistant cells and as inhibitors of specific biological functions, and (v) direct derivatives of classical anticancer platinum drugs in clinical use.
Export Options
About this article
Cite this article as:
Galanski Sophia Mathea*, Recent Developments in the Field of Anticancer Platinum Complexes, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (2) . https://dx.doi.org/10.2174/157489206777442287
DOI https://dx.doi.org/10.2174/157489206777442287 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine N-Succinyl Chitosan as Buccal Penetration Enhancer for Delivery of Herbal Agents in Treatment of Oral Mucositis
Current Drug Delivery Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers
Current Medicinal Chemistry Percutaneous Dilatational Tracheostomy - An Update
Current Respiratory Medicine Reviews CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Human Aurora / Ipl1p Related Kinases
Current Genomics Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Developmental Immunotoxicity (DIT) in Drug Safety Testing: Matching DIT Testing to Adverse Outcomes and Childhood Disease Risk
Current Drug Safety Molecular-Targeted and Cell-Based Therapies for Sjogren’s Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics